相关实验视频

Updated: May 2, 2026

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA

Published on: February 1, 2019

表面工程强大的混合脂质纳米囊:用于mRNA输送的下一代纳米平台

Sunil Kumar Yadava¹, Anuja Tripathi², Mridula Kabilan¹

¹School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA 30332, United States.

Journal of controlled release : official journal of the Controlled Release Society

|October 13, 2025

概括

用L-histidine (hLNC-Hist) 设计的混合脂类纳米囊 (hLNCs) 显示出改善的生物相容性和减少mRNA传递的免疫性. 这种稳定,无冷链的平台非常适合慢性mRNA疗法.

科学领域:

生物技术和纳米医学
药物输送系统药物输送系统
免疫学免疫学免疫学

背景情况:

传统的混合脂质纳米囊 (hLNCs) 使用聚乙烯胺 (PEI) 来输送mRNA,但PEI的高电荷密度会导致细胞毒性和免疫激活,限制慢性使用.
现有的脂质纳米颗粒 (LNP) 可以触发免疫反应和抗PEG抗体,限制长期mRNA疗法的重复剂量.

研究的目的:

设计具有增强生物相容性和降低免疫性的hLNC,以稳定,环境温度的mRNA传递.
评估L-histidine (hLNC-Hist) 和聚乙烯糖醇 (hLNC-PEG) 修改的hLNCs用于mRNA输送的疗效和安全性,特别是用于慢性应用.

主要方法:

用L-histidine (hLNC-Hist) 或短链聚乙烯糖醇 (hLNC-PEG) 修改hLNC的表面.
在体外评估血清蛋白结合,细胞相容性和mRNA转染效率.
在体内mRNA表达的评估,免疫性 (IgM,IgG反应) 和系统管理后的炎症性细胞因子概况.

主要成果:

hLNC-Hist和hLNC-PEG都减少了血清蛋白的结合,并改善了细胞相容性.
与未经修改的hLNC相比,hLNC-Hist在体外转染过程中被保存,并在体内增强mRNA表达,而hLNC-PEG则降低了转染效率.
hLNC-Hist没有显著的IgM或IgG反应,抑制了促炎细胞因子,并保持了糖玻璃中的环境温度mRNA稳定,与传统的LNP不同.

结论:

在慢性mRNA输送中,hLNC-Hist比基于PEI的hLNC和免疫性LNP提供了更好的安全有效性概况.
免疫沉默,生物相容性和hLNC-Hist的热稳定性使其成为在mRNA疗法中无冷链部署的有希望的载体.
hLNC-Hist特别适合在癌症免疫疗法,蛋白质替代和自身免疫调节等新兴疗法中重复使用.

关键词:

混合脂类纳米囊混合脂类纳米囊纳米颗粒纳米颗粒热稳定性热稳定性提供mRNA的交付.

更多相关视频

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Published on: June 10, 2022

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing

Published on: January 20, 2023

相关概念视频

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...